Federal Supply Schedule 36F79723D003E
Award Date
5/18/23
Last Date to Order
11/1/23
Federal Agency
Veterans Integrated Service Network 12
Awardee
Bluebird Bio, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Federal Supply Schedule (FSS) contract, awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 12, allows the VA to procure drugs, pharmaceuticals, and hematology-related products from Bluebird Bio, Inc. through October 2028. The multiple-award, $300,000 contract under Schedule 65 IB enables the VA to acquire Bluebird Bio's gene therapies and hematology products to treat veterans with rare genetic disorders and blood diseases. Additionally, Bluebird Bio...
The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Bluebird Bio, Inc., a biotechnology company focused on developing gene therapies. The BPA, with an estimated value of over $10.6 million, aims to provide Zynteglo, Bluebird Bio's FDA-approved gene therapy for transfusion-dependent beta-thalassemia, to the VA through June 2024. This BPA award demonstrates the VA's interest in utilizing Bluebird Bio's gene therapies and...
The Department of Veterans Affairs (VA) awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products to Provention Bio Inc., a biopharmaceutical company. This FSS contract, awarded by the VA's VISN 12 in July 2023, allows the VA to procure Provention Bio's pharmaceutical products, including TZIELD, to support VA healthcare programs serving veterans. Additionally, the VA National Acquisition Center awarded...
The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
The Federal Supply Schedule (FSS) contract identified as 36F79720D0225 was awarded by the U.S. Department of Veterans Affairs (VA) to Novartis Gene Therapies Inc. on September 15, 2020. This multiple-award, indefinite delivery vehicle (IDV) contract is under the Pharmaceuticals and Drugs (FSS-61-IB) category, with a total ceiling value of $6,000,000,000 and a period of performance extending until September 14, 2026. The purpose of this contract is to provide the VA with a broad range of...
The Department of Veterans Affairs (VA) awarded a multiple-award Federal Supply Schedule (FSS) contract (ID: 36F79724D0101) to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer, with a ceiling value of $12,278,876,570.00 and a period of performance through April 30, 2029. This FSS contract covers a comprehensive range of drugs, pharmaceuticals, and hematology-related products, enabling the VA to efficiently procure innovative medical treatments, particularly advanced oncology and...
The Federal Supply Schedule (FSS) contract #36F79724D017E, awarded to Adma Biologics, Inc., provides the Department of Veterans Affairs (VA) and its Veterans Integrated Service Network 12 (VISN 12) with access to a variety of pharmaceutical and hematology-related products. The contract has a ceiling value of $25,000 and runs through July 14, 2024. Adma Biologics, a for-profit organization, specializes in plasma-derived therapeutics, with specific products referenced including ASCENIV and...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs to Banner Life Sciences LLC, a foreign-owned for-profit organization. The contract is under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule and has a ceiling value of $225,000.00. The period of performance runs from the award date of March 15, 2021 through March 14, 2026. The contract is intended to provide the Department of Veterans Affairs with a range of pharmaceutical and...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs (VA) to Bioxcel Therapeutics, Inc. on February 15, 2023. The contract, identified as 36F79723D0071, has a ceiling value of $2,225,000.00 and a period of performance extending to February 14, 2028. The scope of the contract includes the provision of 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS to the VA's Veterans Integrated Service Network 12. This indicates that the contract is focused...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs (VA) to Intrabio Inc., a small business, for the delivery of drugs, pharmaceuticals, and hematology-related products under Schedule 65 I B. The contract has a ceiling value of $25,000 and a period of performance from February 1, 2025 to July 3, 2025. As an interim agreement, this contract provides the VA with access to Intrabio's catalog of medical products through the Federal Supply Schedule mechanism. The...